Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 5;1(1):55-64.
doi: 10.3109/21556660.2012.672353. eCollection 2012.

The role of the renin-angiotensin system blocking in the management of atrial fibrillation

Affiliations

The role of the renin-angiotensin system blocking in the management of atrial fibrillation

Brett Cliff et al. J Drug Assess. .

Abstract

Objective: To review current available evidence for the role of renin-angiotensin system blockade in the management of atrial fibrillation.

Method: We conducted a PubMed and Medline literature search (January 1980 through July 2011) to identify all clinical trials published in English concerning the use of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers for primary and secondary prevention of atrial fibrillation. We also discussed renin-angiotensin system and its effects on cellular electrophysiology.

Conclusion: The evidence from the current studies discussed does not provide a firm definitive indication for the use of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in the primary or secondary prevention of atrial fibrillation. Nevertheless, modest benefits were observed in patients with left ventricular dysfunction. In view of the possible benefits and the low incidence of side-effects with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, they can be given to patients with recurrent AF, specifically those with hypertension, heart failure and diabetes mellitus.

Keywords: Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Atrial fibrillation; Renin–angiotensin system.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Renin–angiotensin system.

Similar articles

Cited by

References

    1. Chen L. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm. 2007;4:S1-6 - PubMed
    1. Fuster V, Rydén LE, Cannom DS, et al. American College of Cardiology; American Heart Association; European Society of Cardiology. [ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary. Eur Heart J 2006;27:1979-2030 - PubMed
    1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5 - PubMed
    1. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84 - PubMed
    1. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-56 - PubMed

LinkOut - more resources